Corporate Rebranding and Business Expansion
The company has undergone a rebranding from Sattva Sukun Lifecare Limited to Tavexia Lifecare Limited, aligning its corporate identity with high-growth business verticals. The company has altered its Main Object Clause under its Memorandum of Association to expand into new business areas including:
- Active Pharmaceutical Ingredients (APIs) & Bulk Drugs
- Finished Dosage Forms & Formulations (tablets, capsules, injectables, and advanced delivery formats)
- Contract Research and Manufacturing Services (CRAMS) and Contract Development and Manufacturing Organizations (CDMO)
- Nutraceuticals & Biotechnology
Acquisition Details
The Board of Directors approved the acquisition of a 60% controlling equity stake in Meyonex Pharmaceuticals Limited through a cash subscription of 2,09,97,180 fresh equity shares at an issue price of ₹32 per share, totaling ₹67.19 Crore.
Strategic Rationale
The acquisition provides:
- Immediate operational foothold through Meyonex's established manufacturing and commercial operations based in MIDC Tarapur, Maharashtra
- Direct access to high-demand pharma product lines
- Significant synergies and immediate growth runway for scaling revenue baseline
- Operational efficiencies
Funding Plan
To finance this expansion, the management has initiated plans for strategic fund-raising through permissible equity or convertible instruments, maintaining capital discipline while backing accretive growth.
Sector Context
The disclosure mentions sustained tailwinds supporting domestic manufacturing, global supply-chain diversification ("China+1"), and escalating demand for specialized generic formulations and contract manufacturing as favorable sector conditions.